Programmed haploidentical hematopoietic stem cell infusion combined with systemic chemotherapy improves the outcomes of patients with refractory or relapsed lymphoma

Zhao Hong-XiaDepartment of Hematology, the Second Artillery General Hospital, Beijing, China

Sun Wan-JunDepartment of Hematology, the Second Artillery General Hospital, Beijing, ChinaCorrespondence[email protected]

Li JieDepartment of Hematology, the Second Artillery General Hospital, Beijing, China

Hu Hai-LanDepartment of Hematology, the Second Artillery General Hospital, Beijing, China

Ai Hui-ShengDepartment of Hematology, Affiliated Hospital to the Academy of Military Medicine Science, Beijing, China

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Programmed haploidentical hematopoietic stem cell infusion combined with systemic chemotherapy improves the outcomes of patients with refractory or relapsed lymphoma

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

Programmed haploidentical hematopoietic stem cell infusion combined with systemic chemotherapy improves the outcomes of patients with refractory or relapsed lymphoma

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature